Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.
about
Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Österreichische KopfschmerzgesellschLow migraine headache recurrence with naratriptan: clinical parameters related to recurrenceHow does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials.Cardiovascular tolerability and safety of triptans: a review of clinical data.Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine.Naratriptan: an alternative for migraine.Migraine: a comprehensive review of new treatment options.Current and emerging second-generation triptans in acute migraine therapy: a comparative review.Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials.New paradigms in the recognition and acute treatment of migraine.Headache recurrence as a criterion for assessing efficacy of triptans: a perspective.Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability.Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans.Naratriptan in the preventive treatment of refractory chronic migraine: a review of 27 cases.Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.Methodological issues in systematic reviews of headache trials: adapting historical diagnostic classifications and outcome measures to present-day standards.Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a commentPublished and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register.Drug safety in acute migraine treatment.Comparative tolerability of treatments for acute migraine: A network meta-analysis.A model-based approach to treatment comparison in acute migraine.Efficacy of oral naratriptan in the treatment of menstrually related migraine.Effects of naratriptan versus naproxen on daily functioning in the acute treatment of migraine: a randomized, double-blind, double-dummy, crossover study.Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.Dose range-finding studies with frovatriptan in the acute treatment of migraine.Frovatriptan for the acute treatment of migraine: a dose-finding study.Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan.Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study.Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan Long-term Study Group.Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study.Differentiating the efficacy of 5-HT(1B/1D) agonists.Naratriptan prophylactic treatment in cluster headache.Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis.Clinical efficacy of frovatriptan: placebo-controlled studies.[Which triptan is best? Rating of triptans in migraine treatment].Placebo adverse events in headache trials: headache as an adverse event of placebo.The combination of naratriptan and prochlorperazine in migraine treatment.Triptans in the treatment of migraine: drug selection by means of the SOJA method.
P2860
Q24619383-A6F3EEA2-450A-4414-B822-0556F46CA949Q28376494-E84A55C1-F87A-489F-936E-DBAC3579B0C6Q30692301-64977F15-284F-42A6-86CE-99FA800F0C9FQ30932202-7D8C2C87-0F77-4E99-802A-42F65DDCBC98Q31119065-587DD0FF-D3DB-4257-878E-3C112B40C77FQ32039000-D28406EC-2957-4EE7-BB18-4EC4B9405E11Q33689204-9E0F56BC-DD64-4B4D-8AD0-7584F2161623Q33715929-50241BB9-A03F-4202-87C4-D9A771BF887EQ33908453-9B048F27-3DCB-4854-84B0-5DFBB10EC697Q34154647-8C9DF629-DF9D-4E26-A19E-F4D46066FA02Q34634345-1BBCD1DE-2F3B-49EA-AA0B-B00FC96A6499Q34634351-C8C77910-F656-49B0-87D6-F7BEEE6E5D5DQ34691359-529B1977-C8A6-49F2-9F9C-3534E9B90BF7Q35091964-E1E93774-DFFB-4674-95AD-D7F98443BD34Q35129772-6D9A68F6-DBE5-4B59-99EC-63ECD49CA08DQ35775292-CFC4E1FE-0F50-4B04-84C0-72AE3F131B32Q36161561-7D854376-F368-4D76-B00C-2EC641B852EBQ36978875-A7B86A2C-491D-43A2-ACE7-1663DD1904DBQ37857762-FE5AE513-8D6E-4952-AA81-6F75D6385D34Q38378898-007CFC9A-13D5-4468-A2E6-F23DC94DBF3BQ38927015-0148715F-10C8-4311-BCB6-00FBF62B2A88Q39344317-E709140F-F448-4BA8-9F3A-A6187E06C846Q39361381-52E8C090-0E79-4FC7-B614-20E939FFBF42Q39391112-11C5A85E-B1D3-49F5-9431-DC91C1284295Q39404886-B4E55D96-A323-4967-9B8D-1212DC7FE1B6Q39406672-882B2AE9-F462-456C-B9E4-9191AE515A69Q39407202-D0A2637E-F326-426D-8F2A-F6A1D1564809Q39427714-C661D04D-2D3A-4030-853F-AD9C0D17BF45Q39439890-28EBF480-2639-4D30-89F3-33B11815A1BCQ39447979-49F61553-BFDA-4997-B194-CCC2F4AF63B5Q43551354-6F384839-CCDF-4EFA-B27A-93CF3637A5C8Q43551356-B1317896-15C5-4583-BD55-1E35BD12DCAAQ43572330-73CD0539-B112-4C5D-9131-1BA3559817A5Q43622987-A1382BC7-4C9C-4300-9D30-5BC865359D55Q44004697-949308C8-0015-43C1-AC76-9677176CF1A0Q44171180-D75A3A8B-D691-4821-888B-977709616404Q44570003-FB643EE8-158C-4BC3-B741-6AA6D1C531FAQ46543682-23B28226-0A05-4FAA-90A4-265599CAC750Q46955158-48713B71-9895-401F-862E-1D9CBFD63F0D
P2860
Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Naratriptan is effective and w ...... atriptan S2WA3001 Study Group.
@en
Naratriptan is effective and w ...... atriptan S2WA3001 Study Group.
@nl
type
label
Naratriptan is effective and w ...... atriptan S2WA3001 Study Group.
@en
Naratriptan is effective and w ...... atriptan S2WA3001 Study Group.
@nl
prefLabel
Naratriptan is effective and w ...... atriptan S2WA3001 Study Group.
@en
Naratriptan is effective and w ...... atriptan S2WA3001 Study Group.
@nl
P2093
P1433
P1476
Naratriptan is effective and w ...... atriptan S2WA3001 Study Group.
@en
P2093
A Laurenza
M Asgharnejad
P304
P356
10.1046/J.1526-4610.1997.3710640.X
P577
1997-11-01T00:00:00Z